Josep‐María Ribera

23.5k total citations · 2 hit papers
432 papers, 9.6k citations indexed

About

Josep‐María Ribera is a scholar working on Hematology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Josep‐María Ribera has authored 432 papers receiving a total of 9.6k indexed citations (citations by other indexed papers that have themselves been cited), including 187 papers in Hematology, 152 papers in Oncology and 133 papers in Pathology and Forensic Medicine. Recurrent topics in Josep‐María Ribera's work include Lymphoma Diagnosis and Treatment (131 papers), Acute Lymphoblastic Leukemia research (124 papers) and Acute Myeloid Leukemia Research (86 papers). Josep‐María Ribera is often cited by papers focused on Lymphoma Diagnosis and Treatment (131 papers), Acute Lymphoblastic Leukemia research (124 papers) and Acute Myeloid Leukemia Research (86 papers). Josep‐María Ribera collaborates with scholars based in Spain, Italy and United States. Josep‐María Ribera's co-authors include Albert Oriol, Evarist Feliú, Salut Brunet, Jordi Esteve, Jorge Sierra, Marcos González, Fuensanta Millá, Juan‐Manuel Sancho, Armando López‐Guillermo and Renato Bassan and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Josep‐María Ribera

389 papers receiving 9.5k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2016 291 citations D. Hoelzer, Renato Bassan et al. Annals of Oncology profile →
Management of ALL in adults: 2024 ELN recommendations from a European expert panel

2024 45 citations Nicola Gökbuget, Nicolas Boissel et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Josep‐María Ribera Spain	51	4.5k	3.5k	2.8k	2.7k	2.0k	432	9.6k
Ofer Shpilberg Israel	46	3.3k 0.7×	3.7k 1.1×	3.4k 1.2×	816 0.3×	1.9k 0.9×	261	9.2k
Sergio Amadori Italy	58	9.9k 2.2×	3.4k 1.0×	2.3k 0.8×	3.0k 1.1×	4.1k 2.0×	363	15.5k
Franco Mandelli Italy	65	9.0k 2.0×	3.4k 1.0×	2.7k 1.0×	3.6k 1.3×	4.8k 2.4×	484	15.2k
Peter Dreger Germany	58	5.4k 1.2×	4.6k 1.3×	3.7k 1.3×	1.0k 0.4×	1.4k 0.7×	408	11.6k
Jacob M. Rowe Israel	59	7.9k 1.8×	3.0k 0.8×	1.3k 0.5×	5.6k 2.1×	3.0k 1.5×	317	12.9k
Karl G. Blume United States	53	6.7k 1.5×	2.8k 0.8×	1.4k 0.5×	1.6k 0.6×	1.2k 0.6×	162	10.5k
Marcos de Lima United States	62	9.2k 2.0×	3.5k 1.0×	1.1k 0.4×	2.8k 1.1×	2.0k 1.0×	421	12.7k
Mauricette Michallet France	50	6.9k 1.5×	2.6k 0.7×	996 0.4×	1.9k 0.7×	2.0k 1.0×	311	10.0k
John T. Sandlund United States	60	3.4k 0.8×	2.3k 0.7×	1.7k 0.6×	5.8k 2.2×	1.7k 0.9×	169	10.5k
Michael B. Maris United States	50	7.8k 1.7×	2.8k 0.8×	1.1k 0.4×	2.3k 0.9×	1.2k 0.6×	173	11.0k

Countries citing papers authored by Josep‐María Ribera

Since Specialization

Citations

This map shows the geographic impact of Josep‐María Ribera's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Josep‐María Ribera with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Josep‐María Ribera more than expected).

Fields of papers citing papers by Josep‐María Ribera

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Josep‐María Ribera. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Josep‐María Ribera. The network helps show where Josep‐María Ribera may publish in the future.

Co-authorship network of co-authors of Josep‐María Ribera

This figure shows the co-authorship network connecting the top 25 collaborators of Josep‐María Ribera. A scholar is included among the top collaborators of Josep‐María Ribera based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Josep‐María Ribera. Josep‐María Ribera is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gökbuget, Nicola, Nicolas Boissel, Sabina Chiaretti, et al.. (2024). Management of ALL in adults: 2024 ELN recommendations from a European expert panel. Blood. 143(19). 1903–1930. 45 indexed citations breakdown →

Jabbour, Elias, Hagop M. Kantarjian, Nicola Goekbuget, et al.. (2024). Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab. Blood Cancer Journal. 14(1). 203–203. 4 indexed citations

Ribera, Josep‐María, Josep‐María Ribera, Mireia Morgades, et al.. (2024). Ponalfil trial for adults with Philadelphia chromosome‐positive acute lymphoblastic leukemia: Long‐term results. HemaSphere. 8(4). e67–e67. 10 indexed citations

Hoelzer, D., Renato Bassan, Nicolas Boissel, et al.. (2023). ESMO Clinical Practice Guideline interim update on the use of targeted therapy in acute lymphoblastic leukaemia. Annals of Oncology. 35(1). 15–28. 11 indexed citations

Sorigué, Marc, Mark Bishton, Eva Domingo‐Doménech, et al.. (2019). Refractoriness to rituximab-based therapy and elevated serum B2-microglobulin predict for inferior survival in marginal zone lymphoma. Leukemia & lymphoma. 60(10). 2524–2531. 3 indexed citations

Sorigué, Marc, Santiago Mercadal, Gustavo Tapia, et al.. (2019). m7FLIPI and targeted sequencing in high‐risk follicular lymphoma. Hematological Oncology. 37(5). 564–568. 3 indexed citations

Sorigué, Marc, Santiago Mercadal, Sara Alonso, et al.. (2017). Refractoriness to immunochemotherapy in follicular lymphoma: Predictive factors and outcome. Hematological Oncology. 35(4). 520–527. 11 indexed citations

Wei, Andrew H., Josep‐María Ribera, Giovanni Martinelli, et al.. (2017). Baseline Biomarkers Influencing Clinical Outcomes in Adults with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (R/R ALL) Treated with Blinatumomab Versus Standard-of-Care Chemotherapy (SOC) from a Randomized Phase 3 Study. Blood. 130. 2556–2556. 1 indexed citations

Villegas, Ana, Beatriz Arrizabalaga, Santiago Bonanad, et al.. (2016). Consenso español para el diagnóstico y tratamiento de la hemoglobinuria paroxística nocturna. Medicina Clínica. 146(6). 278.e1–278.e7. 12 indexed citations

10.

García‐Sánz, Ramón, Albert Oriol, María José Moreno, et al.. (2015). Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial. Haematologica. 100(9). 1207–1213. 24 indexed citations

11.

Forero‐Castro, Maribel, Cristina Robledo, Eva Lumbreras, et al.. (2015). The presence of genomic imbalances is associated with poor outcome in patients with burkitt lymphoma treated with dose‐intensive chemotherapy including rituximab. British Journal of Haematology. 172(3). 428–438. 16 indexed citations

12.

Juncà, Jordi, Isabel Granada, Anna Torrent, et al.. (2014). Correlation of CD11b and CD56 expression in adult acute myeloid leukemia with cytogenetic risk groups and prognosis. Annals of Hematology. 93(9). 1483–1489. 21 indexed citations

13.

Díaz‐Beyá, Marina, Salut Brunet, Josep Nomdedéu, et al.. (2013). MicroRNA expression at diagnosis adds relevant prognostic information to molecular categorization in patients with intermediate-risk cytogenetic acute myeloid leukemia. Leukemia. 28(4). 804–812. 47 indexed citations

14.

Morgades, Mireia, Alícia Lacoma, Pilar Marcos, et al.. (2012). Lack of impact of human immunodeficiency virus infection on the outcome of lymphoma patients transferred to the intensive care unit. Leukemia & lymphoma. 53(10). 1966–1970. 7 indexed citations

15.

Cobo, Erik, Jordi Cortés, Josep‐María Ribera, et al.. (2011). Effect of using reporting guidelines during peer review on quality of final manuscripts submitted to a biomedical journal: masked randomised trial. BMJ. 343(nov22 2). d6783–d6783. 168 indexed citations

16.

Lahuerta, Juan José, María‐Victoria Mateos, Joaquín Martínez‐López, et al.. (2008). Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival. Journal of Clinical Oncology. 26(35). 5775–5782. 193 indexed citations

17.

Berenguer, Juan, Pilar Miralles, Josep‐María Ribera, et al.. (2008). Characteristics and Outcome of AIDS-Related Hodgkin Lymphoma Before and After the Introduction of Highly Active Antiretroviral Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes. 47(4). 422–428. 64 indexed citations

18.

Muchart, Jordi, et al.. (1996). Occlusion of the superior mesenteric artery in a patient with Polycythemia vera: Resolution with percutaneous transluminal angioplasty. Annals of Hematology. 72(2). 89–91. 8 indexed citations

19.

Navarro, José‐Tomás, Josep‐María Ribera, Manuel Vaquero Abellán, et al.. (1995). Erythema nodosum as a presenting feature of T-cell-rich B-cell lymphoma. Annals of Hematology. 70(2). 107–108. 6 indexed citations

20.

Navarro, José‐Tomás, et al.. (1995). Erythema nodosum as a presenting feature of T-cell-rich B-cell lymphoma. Annals of Hematology. 70(2). 107–108. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact